Effects of Neutrophil/Lymphocyte, Platelet/Lymphocyte, CRP/Albumin and Lactate on Mortality in Trauma Patients Admitted to Intensive Care
NCT ID: NCT06667310
Last Updated: 2025-05-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
150 participants
OBSERVATIONAL
2024-11-05
2025-05-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ICU Mortality Predictors of Trauma Patients
NCT03894111
CT Indices Analysis in ICU Pneumonia Patients With Acute Respiratory Failure (CT:Computed Tomography, ICU: Intensive Care Unit)
NCT06651931
Effect of Blood Group on the Survival Status of Intensive Care Patients
NCT04460625
Neutrophil Lymphocyte Ratio as a Predictor of Outcome in Critically Traumatic Patients
NCT02749487
Investigation of the Relationship Between Nutritional Status Assessment and Frailty in Critical Care Patients
NCT07143084
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2\. Patients whose data is missing or whose data cannot be accessed.
1 Year
95 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Harran University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Veli Fahri Pehlivan
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Veli Fahri Pehlivan
Karaköprü, Şanliurfa, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hasan
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.